Evaluation of the effectiveness of liverin in the complex treatment of various hemodynamic phenotypes of chronic heart failure

Abstract

to evaluate the effectiveness of Liverin's influence on the processes of fibrosis of the heart and target organs, including the liver, in different hemodynamic phenotypes of chronic heart failure. Materials and methods: The effect of the drug Liverin on the heart and target organs, including the liver, was studied in 123 patients with CHF with various types of left ventricular ejection fraction. The patients were divided into 2 groups, the 1 st group included 64 patients, the 2 nd group - 59 patients with CHF. Patients of the 1st group with CHF against the background of standard treatment received the drug Liverin at a dose of 600 mg - 2 ml intravenously for 7 days, after which this drug was prescribed 2 capsules 3 times a day for 3 months. Patients in Group 2 received only standard treatment. After the therapy, 3 months later, the function of the right chambers of heart were assessed using chocardiography and the degree of liver fibrosis was assessed by liver elastography and the levels of galectin-3 and aldosterone in the blood serum were determined.